L3VLUP
ProSign in

ALLO · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ALLOGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ALLO
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterALLOGILD
Q3 20209 holders, $702m25 holders, $14.2bn
Q4 20205 holders, $462m27 holders, $13.4bn
Q1 20217 holders, $666m24 holders, $14.5bn
Q2 20218 holders, $321m18 holders, $14.9bn
Q3 20215 holders, $302m20 holders, $16.4bn
Q4 20213 holders, $10m20 holders, $16.8bn
Q1 20223 holders, $6.5m28 holders, $13.2bn
Q2 20223 holders, $79m26 holders, $13.6bn
Q3 20224 holders, $60m24 holders, $13.3bn
Q4 20222 holders, $26m32 holders, $21.1bn
Q1 20232 holders, $11m27 holders, $21.8bn
Q2 20232 holders, $27m24 holders, $20.7bn
Q3 20233 holders, $18m24 holders, $20.0bn
Q4 20232 holders, $11m22 holders, $21.5bn
Q1 20243 holders, $15m30 holders, $20.3bn
Q2 20243 holders, $27m28 holders, $18.5bn
Q3 20244 holders, $37m29 holders, $24.2bn
Q4 20243 holders, $24m28 holders, $25.9bn
Q1 20252 holders, $24m33 holders, $32.0bn
Q2 20251 holders, $13m27 holders, $30.9bn
Q3 2025none listed holders, n.a.23 holders, $29.4bn
Q4 2025none listed holders, n.a.25 holders, $34.3bn
Q1 2026none listed holders, n.a.25 holders, $38.5bn
Q2 2026none listed holders, n.a.26 holders, $34.2bn
ALLO

Allogene Therapeutics Inc

Holders
0
Reported value
$0
Buyers
18
Sellers
10

Breadth +8 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
26
Reported value
$34.2bn
Buyers
22
Sellers
16

Breadth +6 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2026

Among the 26 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only ALLO (0)

None.

Only GILD (26)

AllianceBernstein LP, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Quantbot Technologies LP, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Voloridge Investment Management LLC, Wellington Management Group LLP, and 1 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →